Image source: Getty Images.
It’s been a long and winding road for investors in Sarepta Therapeutics (NASDAQ: SRPT), but shareholders who stuck with the company through thick and thin finally have been rewarded for their patience.
Image source: Getty Images.
It’s been a long and winding road for investors in Sarepta Therapeutics (NASDAQ: SRPT), but shareholders who stuck with the company through thick and thin finally have been rewarded for their patience.